Tumour suppressors in liver carcinogenesis

被引:11
作者
Dufour, Jean-Francois [1 ]
Huber, Otmar
Kozma, Sara C.
Lu, Xin
Toftgard, Rune
机构
[1] Univ Bern, Inst Clin Pharmacol, Bern, Switzerland
[2] Charite, Dept Lab Med & Pathobiochem, Berlin, Germany
[3] Univ Cincinnati, Genome Res Inst, Cincinnati, OH USA
[4] Ludwig Inst Canc Res, London W1P 8BT, England
[5] Karolinska Inst, Ctr Biosci, Dept Biosci & Nutr, Huddinge, Sweden
关键词
D O I
10.1016/j.jhep.2007.09.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The circuitous cell signalling pathways of hepatocytes comprise several factors that operate to downgrade or even interrupt the transmission of a given signal. These down-regulating influences are essential to keep cell proliferation and cell survival in check and if impaired, can alter a delicate balance in favour of cell proliferation. Each signalling pathway that has been implicated in carcinogenesis is influenced by both oncogenic factors that promote tumour growth when activated as well as tumour suppressor proteins that have to be impaired to favour tumour growth. This summary of the Tumour Suppressors in Liver Carcinogenesis Symposium held at the 2007 EASL Annual Meeting discusses four pathways with pre-eminent tumour suppressor activity, each involved in hepatocarcinogenesis: p53, mTOR, beta-catenin and hedgehog. (c) 2007 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:860 / 867
页数:8
相关论文
共 85 条
[1]
Patched1 functions as a gatekeeper by promoting cell cycle progression [J].
Adolphe, C ;
Hetherington, R ;
Ellis, T ;
Wainwright, B .
CANCER RESEARCH, 2006, 66 (04) :2081-2088
[2]
GEOGRAPHIC-VARIATION OF P53 MUTATIONAL PROFILE IN NONMALIGNANT HUMAN LIVER [J].
AGUILAR, F ;
HARRIS, CC ;
SUN, T ;
HOLLSTEIN, M ;
CERUTTI, P .
SCIENCE, 1994, 264 (5163) :1317-1319
[3]
Mechanism of activation of protein kinase B by insulin and IGF-1 [J].
Alessi, DR ;
Andjelkovic, M ;
Caudwell, B ;
Cron, P ;
Morrice, N ;
Cohen, P ;
Hemmings, BA .
EMBO JOURNAL, 1996, 15 (23) :6541-6551
[4]
Pontin52 and Reptin52 function as antagonistic regulators of β-catenin signalling activity [J].
Bauer, A ;
Chauvet, S ;
Huber, O ;
Usseglio, F ;
Rothbächer, U ;
Aragnol, D ;
Kemler, R ;
Pradel, J .
EMBO JOURNAL, 2000, 19 (22) :6121-6130
[5]
Pontin52, an interacticon partner of β-catenin, binds to the TATA box binding protein [J].
Bauer, A ;
Huber, O ;
Kemler, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :14787-14792
[6]
Medulloblastoma growth inhibition by Hedgehog pathway blockade [J].
Berman, DM ;
Karhadkar, SS ;
Hallahan, AR ;
Pritchard, JI ;
Eberhart, CG ;
Watkins, DN ;
Chen, JK ;
Cooper, MK ;
Taipale, J ;
Olson, JM ;
Beachy, PA .
SCIENCE, 2002, 297 (5586) :1559-1561
[7]
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation [J].
Beuvink, I ;
Boulay, A ;
Fumagalli, S ;
Zilbermann, F ;
Ruetz, S ;
O'Reilly, T ;
Natt, F ;
Hall, J ;
Lane, HA ;
Thomas, G .
CELL, 2005, 120 (06) :747-759
[8]
The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[9]
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells [J].
Boulay, A ;
Zumstein-Mecker, S ;
Stephan, C ;
Beuvink, I ;
Zilbermann, F ;
Haller, R ;
Tobler, S ;
Heusser, C ;
O'Reilly, T ;
Stolz, B ;
Marti, A ;
Thomas, G ;
Lane, HA .
CANCER RESEARCH, 2004, 64 (01) :252-261